Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2

Vaccine

Volumn 28, Issue 10, 2010, Pages 2243-2248

  Zaman, Mehfuz ^a   Abdel Aal, Abu Baker M ^a   Phillipps, Karen S M ^a   Fujita, Yoshio ^a   Good, M F ^b   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Group A streptococcus (GAS); Lipoamino acid (LAA); Toll like receptor (TLR)

Indexed keywords

EPITOPE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPEPTIDE; STREPTOCOCCUS VACCINE; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 2;

ARTICLE; B LYMPHOCYTE; CELL STRAIN HEK293; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; GROUP A STREPTOCOCCAL INFECTION; HELPER CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; T LYMPHOCYTE; VACCINE PRODUCTION;

ANTIGENS, BACTERIAL; CELL LINE; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENES, REPORTER; HUMANS; LIPOPEPTIDES; LUCIFERASES; NF-KAPPA B; RECOMBINANT PROTEINS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 2;

EID: 77049085233     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.046     Document Type: Article

References (38)

1. Carapetis J.R., Steer A.C., Mulholland E.K., and Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 5 November (11) (2005) 685-694
2. Good M.F., Xu H., and Batzloff M. Adapting immunity with subunit vaccines: case studies with group A Streptococcus and malaria. Int J Parasitol 32 May (5) (2002) 575-580
3. Olive C. Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease. Curr Opin Mol Ther 9 February (1) (2007) 25-34
4. Purcell A.W., McCluskey J., and Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6 May (5) (2007) 404-414
5. Moyle P.M., and Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem 15 5 (2008) 506-516
6. Olive C., Toth I., and Jackson D. Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem 1 November (4) (2001) 429-438
7. Bourel-Bonnet L., Bonnet D., Malingue F., Gras-Masse H., and Melnyk O. Simultaneous lipidation of a characterized peptide mixture by chemoselective ligation. Bioconjug Chem 14 March-April (2) (2003) 494-499
8. BenMohamed L., Wechsler S.L., and Nesburn A.B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2 July (7) (2002) 425-431
9. Toth I. A novel chemical approach to drug delivery: lipidic amino acid conjugates. J Drug Target 2 3 (1994) 217-239
10. Blanchfield J.T., Dutton J.L., Hogg R.C., Gallagher O.P., Craik D.J., Jones A., et al. Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of alpha-conotoxin MII. J Med Chem 46 March (7) (2003) 1266-1272
11. Brown L.E., and Jackson D.C. Lipid-based self-adjuvanting vaccines. Curr Drug Deliv 2 October (4) (2005) 383-393
12. Zhu X., Ramos T.V., Gras-Masse H., Kaplan B.E., and BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol 34 November (11) (2004) 3102-3114
13. Into T., Dohkan J., Inomata M., Nakashima M., Shibata K., and Matsushita K. Synthesis and characterization of a dipalmitoylated lipopeptide derived from paralogous lipoproteins of Mycoplasma pneumoniae. Infect Immun 75 May (5) (2007) 2253-2259
14. Buwitt-Beckmann U., Heine H., Wiesmuller K.H., Jung G., Brock R., Akira S., et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 281 April (14) (2006) 9049-9057
15. Kawai T., and Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 1143 November (2008) 1-20
16. Abdel-Aal A.B., Batzloff M.R., Fujita Y., Barozzi N., Faria A., Simerska P., et al. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem 51 January (1) (2008) 167-172
17. Gibbons W.A., Hughes R.A., Charalambous M., Christodoulou M., Szeto A., et al. Lipidic peptides. 1. Synthesis, resolution and structural elucidation of lipidic amino-acids and their homo-oligomers and heterooligomers. Liebigs Ann Chem January (1990) 1175-1183
18. Tomsig J.L., Sohma H., and Creutz C.E. Calcium-dependent regulation of tumour necrosis factor-alpha receptor signalling by copine. Biochem J 378 March (Pt 3) (2004) 1089-1094
19. Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 6 June (6) (2005) 571-578
20. Pecora N.D., Gehring A.J., Canaday D.H., Boom W.H., and Harding C.V. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J Immunol 177 July (1) (2006) 422-429
21. Muta T., and Takeshige K. Essential roles of CD14 and lipopolysaccharide-binding protein for activation of toll-like receptor (TLR)2 as well as TLR4 Reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations. Eur J Biochem 268 August (16) (2001) 4580-4589
22. Zeng W., Ghosh S., Lau Y.F., Brown L.E., and Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 169 November (9) (2002) 4905-4912
23. Buwitt-Beckmann U., Heine H., Wiesmuller K.H., Jung G., Brock R., and Ulmer A.J. Lipopeptide structure determines TLR2 dependent cell activation level. FEBS J 272 December (24) (2005) 6354-6364
24. Chua B.Y., Zeng W., Lau Y.F., and Jackson D.C. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 25 January (1) (2007) 92-101
25. Borsutzky S., Kretschmer K., Becker P.D., Muhlradt P.F., Kirschning C.J., Weiss S., et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 174 May (10) (2005) 6308-6313
26. Abrahams V.M., Aldo P.B., Murphy S.P., Visintin I., Koga K., Wilson G., et al. TLR6 modulates first trimester trophoblast responses to peptidoglycan. J Immunol 180 May (9) (2008) 6035-6043
27. Farhat K., Riekenberg S., Heine H., Debarry J., Lang R., Mages J., et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol 83 March (3) (2008) 692-701
28. Buwitt-Beckmann U., Heine H., Wiesmuller K.H., Jung G., Brock R., Akira S., et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 35 January (1) (2005) 282-289
29. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 January (1) (2006) 49-55
30. Lahiri A., Das P., and Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26 December (52) (2008) 6777-6783
31. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 27 July (4) (2007) 363-371
32. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 April (4 Suppl.) (2005) S45-S53
33. Ulitzur S. The amphiphatic nature of Prymnesium parvum hemolysin. Biochim Biophys Acta 298 March (3) (1973) 673-679
34. Toth I., Anderson G.J., Hussain R., Wood I.P., Fernandez E.D.O., Ward P., et al. Lipidic peptides. X. Synthesis, structural and physicochemical elucidation of lipidic amino acid conjugates with hydrophilic compounds. Tetrahedron 48 (1992) 923-930
35. Sabroe I., Read R.C., Whyte M.K., Dockrell D.H., Vogel S.N., and Dower S.K. Toll-like receptors in health and disease: complex questions remain. J Immunol 171 August (4) (2003) 1630-1635
36. Reschner A., Moretta A., Landmann R., Heberer M., Spagnoli G.C., and Padovan E. The ester-bonded palmitoyl side chains of Pam3CysSerLys4 lipopeptide account for its powerful adjuvanticity to HLA class I-restricted CD8+ T lymphocytes. Eur J Immunol 33 July (7) (2003) 2044-2052
37. Olive C., Batzloff M.R., Horvath A., Wong A., Clair T., Yarwood P., et al. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 70 May (5) (2002) 2734-2738
38. Chua B.Y., Healy A., Cameron P.U., Stock O., Rizkalla M., Zeng W., et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol 81 February (1) (2003) 67-72